Clinical evaluation and optimal management of cancer cachexia

Critical Reviews in Oncology/Hematology

Volumn 88, Issue 3, 2013, Pages 625-636

  Tuca, Albert ^a   Jimenez Fonseca, Paula ^b   Gascón, Pere ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

^b HOSPITAL UNIVERSITARIO CENTRAL DE ASTURIAS   (Spain)

Author keywords

Anorexia; Cachexia; Cancer; Malnutrition; Megestrol acetate

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR BLOCKING AGENT; BORTEZOMIB; CYCLOOXYGENASE 2 INHIBITOR; DEXAMETHASONE; DRONABINOL; GHRELIN; ICOSAPENTAENOIC ACID; INTERLEUKIN 6 ANTIBODY; MEGESTROL ACETATE; MELANOCORTIN; METHYLPREDNISOLONE; METOCLOPRAMIDE; OMEGA 3 FATTY ACID; PIZOTIFEN; PLACEBO; PREDNISONE; SELECTIVE ANDROGEN RECEPTOR MODULATOR; THALIDOMIDE;

ADRENAL INSUFFICIENCY; ANOREXIA; ASTHENIA; BASAL METABOLIC RATE; BODY COMPOSITION; BODY FAT; CACHEXIA; CALORIC INTAKE; CANCER ANOREXIA CACHEXIA SYNDROME; CANCER PATIENT; CARDIOVASCULAR DISEASE; CAUSE OF DEATH; COGNITIVE DEFECT; CONSTIPATION; DIFFERENTIAL DIAGNOSIS; DRUG EFFICACY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSGEUSIA; DYSPHAGIA; EDEMA; EUPHORIA; FLUID RETENTION; GLUCONEOGENESIS; GLUCOSE INTOLERANCE; HALLUCINATION; HIGH RISK PATIENT; HUMAN; HYPERGLYCEMIA; HYPERLIPIDEMIA; INSULIN RESISTANCE; INTESTINE OBSTRUCTION; LIPOLYSIS; MALABSORPTION; MENSTRUATION DISORDER; MUCOSA INFLAMMATION; MUSCLE MASS; MYELOMA; MYOPATHY; NAUSEA; NUTRITIONAL INTOLERANCE; NUTRITIONAL SUPPORT; ODYNOPHAGIA; PATHOPHYSIOLOGY; PREVALENCE; PROTEIN DEGRADATION; PROTEIN INTAKE; PSYCHOSIS; QUALITY OF LIFE; RASH; RESTING ENERGY EXPENDITURE; REVIEW; SARCOPENIA; SIDE EFFECT; SKIN FRAGILITY; SLEEP DISORDER; THROMBOSIS; VERTIGO; WEIGHT REDUCTION;

ANOREXIA; CACHEXIA; CANCER; MALNUTRITION; MEGESTROL ACETATE;

CACHEXIA; HUMANS; NEOPLASMS;

EID: 84888306545     PISSN: 10408428     EISSN: 18790461     Source Type: Journal    
DOI: 10.1016/j.critrevonc.2013.07.015     Document Type: Review

References (85)

1. Blum D., Omlin A., Baracos V.E., et al. Cancer cachexia: a systematic literature review of items and domains associated with involuntary weight loss in cancer. Critical Reviews Oncology/Hematology 2011, 80(1):114-144.
2. Tuca Rodríguez A., Calsina-Berna A., González-Barboteo J., Gómez-Batiste Alentorn X. Cancer cachexia. Medicina Clinica 2010, 135(12):568-572.
3. Jacquelin-Ravel N., Pichard C. Clinical nutrition, body composition and oncology: a critical literature review of the synergies. Critical Reviews in Oncology/Hematology 2012, 84(1):37-46.
4. Evans W.J., Morley J.E., Argilés J., et al. Cachexia: a new definition. Clinical Nutrition 2008, 27(6):793-799.
5. Fearon KC The 2011 ESPEN Arvid Wretlind lecture: cancer cachexia: the potential impact of translational research on patient-focused outcomes. Clinical Nutrition 2012, 31(5):577-582.
6. Temel J.S., Greer J.A., Muzikansky A., et al. Early palliative care for patients with metastatic non-small-cell lung cancer. New England Journal of Medicine 2010, 363(8):733-742.
7. Evans J.K. Skeletal muscle loss: cachexia, sarcopenia, and inactivity. American Journal of Clinical Nutrition 2010, 91(4):1123S-1127S.
8. Argilés J.M., Olivan M., Busquets S., López-Soriano F.J. Optimal management of cancer anorexia-caquexia syndrome. Cancer Management and Research 2010, 2:27-38.
9. Fearon K.C., Glass D.J., Guttridge D.C. Cancer cachexia: mediators, signaling, and metabolic pathways. Cell Metabolism 2012, 16(2):153-166.
10. Fearon K., Strasser F., Anker S.D., et al. Definition and classification of cancer cachexia: an international consensus. Lancet Oncology 2011, 12(5):489-495.
11. Sarhill N., Mahmoud F., Walsh D., et al. Evaluation of nutritional status in advanced metastatic cancer. Supportive Care in Cancer 2003, 11(10):652-659.
12. Segura A., Pardo J., Jara C., et al. An epidemiological evaluation of the prevalence of malnutrition in Spanish patients with locally advanced or metastatic cancer. Clinical Nutrition 2005, 24(5):801-814.
13. Bruera E., Sweeney C. Cachexia and asthenia in cancer patients. Lancet Oncology 2000, 1:138-147.
14. Dewys W.D., Begg C., Lavin P.T., et al. Prognostic effect of weight loss prior to chemotherapy in cancer patients. Eastern Cooperative OncologyGroup. American Journal of Medicine 1980, 69(4):491-497.
15. Argilés J.M., Busquets S., López-Soriano J.F., Figueras M. Fisiopatología de la caquexia neoplásica. Nutrición hospitalaria 2006, 21:4-9.
16. Dimitriu C., Martignoni M.E., Bachmann J., et al. Clinical impact of cachexia on survival and outcome of cancer patients. Romanian Journal of Internal Medicine 2005, 43(3-4):173-185.
17. Holmes S. A difficult clinical problem: diagnosis, impact and clinical management of cachexia in palliative care. International Journal of Palliative Nursing 2009, 15(7):322-326.
18. Argilés J.M., Busquets S., Toledo M., López-Soriano F.J. Mechanisms and treatment of cancer cachexia. Current Opinion in Supportive and Palliative Care 2009, 3(4):263-268.
19. Argiles J.M., Lopez-Soriano F.J., Busquets S. Counteracting inflammation: a promising therapy in cachexia. Critical Reviews in Oncogenesis 2012, 17(3):253-262.
20. Argilés J.M., Moore-Carrasco R., Busquets S., López-Soriano F.J. Catabolic mediators as targets for cancer cachexia. Drug Discovery Today 2003, 8:838-844.
21. Gupta D., Lis C.G., Dahlk S.L., Vashi P.G., Grutsch J.F., Lammersfeld C.A. Bioelectrical impedance phase angle as a prognostic indicator in advanced pancreatic cancer. British Journal of Nutrition 2004, 92(6):957-962.
22. Gupta D., Lammersfeld C.A., Burrows J.L., et al. Bioelectrical impedance phase angle in clinical practice: implications for prognosis in advanced colorectal cancer. American Journal of Clinical Nutrition 2004, 80(6):1634-1638.
23. Davis M.P., Yavuzsen T., Khoshknabi D., et al. Bioelectrical impedance phase angle changes during hydration and prognosis in advanced cancer. American Journal of Hospice and Palliative Care 2009, 26(3):180-187.
24. Paiva S.I., Borges L.R., Halpern-Silveira D., Assunção M.C., Barros A.J., Gonzalez M.C. Standardized phase angle from bioelectrical impedance analysis as prognostic factor for survival in patients with cancer. Supportive Care in Cancer 2010, 19(2):187-192.
25. Prado C.M., Lieffers J.R., McCargar L.J., et al. Prevalence and clinical implications of sarcopenic obesity in patients with solid tumours of the respiratory and gastrointestinal tracts: a population based study. Lancet Oncology 2002, 26(7):953-960.
26. Prado C.M., Baracos V.E., McCargar L.J., et al. Sarcopenia as a determinant of chemotherapy toxicity and time tumor progression in metastatic breast cancer patients receiving capecitabine treatment. Clinical Cancer Research 2009, 15(8):2920-2926.
27. Kubrak C., Jensen L. Critical evaluation of nutrition screening tools recommended for oncology patients. Cancer Nursing 2007, 30(5):E1-E6.
28. Isenring E., Cross G., Daniels L., Kellett E., Koczwara B. Validity of the malnutrition screening tool as an effective predictor of nutritional risk in oncology outpatients receiving chemotherapy. Supportive Care in Cancer 2006, 14(11):152-156.
29. Detsky A.S., McLaughin J.R., Baker J.P., et al. What is subjective global assessment of nutritional status?. Journal of Parenteral and Enteral Nutrition 1987, 11(1):8-13.
30. Ottery F.D. Oncology patient-generated SGA of nutritional status. Nutrition Oncology 1994, 1(2):9.
31. Baker J.P., Destky A.S., Wesson D.E., et al. Nutritional assessment: a comparison of clinical judgement and objective measures. New England Journal of Medicine 1982, 306(16):969-972.
32. Gómez-Candela C., Luengo L.M., Cos A.I., et al. Valoración subjetiva global en el paciente neoplásico desarrollada por servicios de nutrición vs oncología. ¿Es siempre útil evaluar el estado nutricional?. Nutricion Hospitalaria 2003, 18:353-357.
33. Ribaudo J.M., Cella D., Hahn E.A., et al. Revalidation and shortening of the functional assessment anorexia/caquexia therapy (FAACT) questionnaire. Quality of Life Research 2001, 9(10):1137-1146.
34. Cella D.F., Tulsky D.S., Gray G., et al. The functional assessment of cancer therapy scale: development and validation of the general measure. Journal of Clinical Oncology 1993, 11(3):570-579.
35. Bozzetti F., Mariani L. Defining and classifying cancer cachexia: a proposal by the SCRINIO Working Group. Journal of Parenteral and Enteral Nutrition 2009, 33(4):361-367.
36. Blum D., Omlin A., Fearon K., et al. Evolving classification systems in cancer cachexia: ready for clinical practice?. Supportive Care in Cancer 2010, 18(3):273-279.
37. Reid J., McKenna H., Fitzsimons D., McCance T. Fighting over food: patient and family understanding of cancer cachexia. Oncology Nursing Forum 2009, 36(4):439-445.
38. Strasser F., Binswanger J., Cerny T., Kesselring A. Fighting a losing battle: eating related distress of men with advanced cancer and their females partners. A mixed-methods study. Palliative Medicine 2007, 21(2):129-137.
39. Oi-Ling K., Man-Wah D.T., Kam-Hung D.N. Symptom distress as rated by advanced cancer patients, caregivers and physicians in the last week of life. Palliative Medicine 2005, 19(3):228-233.
40. Codorniu N., Mate J., Lliró X., et al. Alteración de la imagen corporal en los pacientes con cáncer avanzado: estudio descriptivo, prospectivo, multicéntrico. Free oral communication presented at: Congreso de la Sociedad Española de Cuidados Paliativos [Congress of Spanish Palliative Care Society] 2010, Abstract of oral communications number 14.
41. Mantovani G., Madeddu C. Cancer caquexia: medical management. Supportive Care in Cancer 2010, 18(1):1-9.
42. Loprinzi C.L., Ellison N.M., Schaid D.J., et al. Controlled trial of megestrol acetate for the treatment of cancer anorexia and cachexia. Journal of the National Cancer Institute 1990, 82(13):1.127-1.132.
43. Loprinzi C.L., Ellison N.M., Goldberg R.M., Michalak J.C., Burch P.A. Alleviation of cancer anorexia and cachexia: studies of the Mayo Clinic and the North Central Cancer Treatment Group. Seminars in Oncology 1990, 17(6 Suppl. 9):8-12.
44. Bruera E., Macmillan K., Kuehn N., Hanson J., MacDonald R.N. A controlled trial of megestrol acetate on appetite, caloric intake, nutritional status, and other symptoms in patients with advanced cancer. Cancer 1990, 66(6). 1. 279-1.282.
45. (accessed 09.11.12). http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.DrugDetails.
46. Pérez De Oteyza C., García Cortés A., Menéndez Martínez M.A., Torres Léon J.M., Pérez Aznar C., Carnicero Bujarrabal M. Megestrol in the treatment of AIDS associated cachexia. Evaluation by bioelectric impedance analysis of body composition. Anales de Medicina Interna 1998, 15(5):255-258.
47. Yeh S.S., Wu S.Y., Lee T.P., et al. Improvement in quality-of-life measures and stimulation of weight gain after treatment with megestrol acetate oral suspension in geriatric cachexia: results of a double-blind, placebo-controlled study. Journal of the American Geriatrics Society 2000, 48(5):485-492.
48. Yeh S.S., Wu S.Y., Levine D.M., et al. The correlation of cytokine levels with body weight after megestrol acetate treatment in geriatric patients. Journals of Gerontology. Series A, Biological Sciences and Medical Sciences 2001, 56(1):M48-M54.
49. Lai Y.L., Fang F.M., Yeh C.Y. Management of anorexic patients in radiotherapy: a prospective randomized comparison of megestrol and prednisolone. Journal of Pain and Symptom Management 1994, 9(4):265-268.
50. Loprinzi C.L., Kugler J.W., Sloan J.A., et al. Randomized comparison of megestrol acetate versus dexamethasone versus fluoxymesterone for the treatment of cancer anorexia/cachexia. Journal of Clinical Oncology 1999, 17(10):3.299-3.306.
51. Jatoi A., Windschitl H.E., Loprinzi C.L., et al. Dronabinol versus megestrol acetate versus combination therapy for cancer-associated anorexia: a North Central Cancer Treatment Group Study. Journal of Clinical Oncology 2002, 20(2):567-573.
52. Jatoi A., Rowland K., Loprinzi C.L., et al. An eicosapentaenoic acid supplement versus megestrol acetate versus both per patients with cancer-associated wasting: a North Central Cancer Treatment Group and National Cancer Institute of Canada Collaborative Effort. Journal of Clinical Oncology 2004, 22(12):2. 469-2.476.
53. Chen H.C., Leung S.W., Wang C.J., Sun L.M., Fang F.M., Hsu J.H. Effect of megestrol acetate and prepulsid on nutritional improvement in patients with head and neck cancers undergoing radiotherapy. Radiotherapy and Oncology 1997, 43(1):75-79.
54. Oberhoff C., Hoffmann O., Winkler U.H., Schindler A.E. Hemostatic effects of high-dose megestrol acetate therapy in patients with advanced gynecological cancer. Gynecological Endocrinology 2001, 15(5):341-348.
55. Pascual López A., Roqué i Figuls M., Urrútia Cuchi G., et al. Systematic review of megestrol acetate in the treatment of anorexia-cachexia syndrome. Journal of Pain and Symptom Management 2004, 27(4):360-369.
56. Berenstein E.G., Ortiz Z. Acetato de megestrol para el tratamiento del síndrome anorexia-caquexia (Revisión Cochrane traducida). La Biblioteca Cochrane Plus, n°. 4 2008, Update Software Ltd., Oxford, (Translated by: The Cochrane Library, 2008, issue 3. Chichester, UK: John Wiley & Sons, Ltd.). http://www.update-software.com/.
57. Lesniak W., Bała M., Jaeschke R., Krzakowski M. Effects of megestrol acetate in patients with cancer anorexia-cachexia syndrome - a systematic review and meta-analysis. Polskie Archiwum Medycyny Wewnetrznej 2008, 118(11):636-644.
58. Maddedu C., Maccio A., Panzone F., Tanca F.M., Mantovani G. Medroxyprogesterone acetate in the management of cancer cachexia. Expert Opinion on Pharmacotherapy 2009, 10(8):1359-1366.
59. Nelson K., Walsh D., Deeter P., Sheehan F. A phase II study of delta-9-tetrahydro-cannabinol for appetite stimulation in cancer-associated anorexia. Journal of Palliative Care 1994, 10(1):14-18.
60. Walsh D., Nelson K.A., Mahmoud F.A. Established and potential therapeutic applications of cannabinoids in oncology. Supportive Care in Cancer 2003, 11(3):137-143.
61. Bruera E., Castro M. Cannabinoids in supportive care: are they necessary?. Supportive Care in Cancer 2003, 11(3):133-134.
62. Bruera E., Strasser F., Palmer J.L., et al. Effect of fish oil on appetite and other symptoms in patients with advanced cancer and anorexia/cachexia: a double blind, placebo and controlled study. Journal of Clinical Oncology 2003, 21(1):129-143.
63. Fearon K.C., Barber M.D., Moses A.G., et al. Double-blind, placebo-controlled, randomized study of eicosapentaenoic acid diester in patients with cancer cachexia. Journal of Clinical Oncology 2006, 24(21):3401-3407.
64. Persson C., Glimelius B., Rönnelid J., Nygren P. Impact of fish oil and melatonin on cachexia in patients with advanced gastrointestinal cancer: a randomized pilot study. Nutrition 2005, 21(2):170-178.
65. Dewey A., Baughan C., Dean T., Higgins B., Johnson I. Eicosapentaenoic acid (EPA, an omega-3 fatty acid from fish oils) for the treatment of cancer cachexia. Cochrane Database Systematic Review 2007, CD004597.
66. Mazzotta P., Jeney C. Anorexia-cachexia syndrome: a systematic review of the role of dietary polyunsaturated taffy acids in the management of symptoms, survival, and quality of life. Journal of Pain and Symptom Management 2008, 37(6):1069-1077.
67. Kardinal C.G., Loprinzi C.L., Scahid D.J., et al. A controlled trial of cyproheptadine in cancer patients with anorexia and/or cachexia. Cancer 1990, 65(12):2657-2662.
68. Couluris M., Mayer J.L., Freyer D.R., Sandler E., Xu P., Krischer J.P. The effect of cyproheptadine hydrochloride (periactin) and megestrol acetate (megace) on weight in children with cancer/treatment-related cachexia. Journal of Pediatric Hematology/Oncology 2008, 30(11):791-797.
69. Lai V., George J., Richey L., et al. Results of a pilot study of the effects of celecoxib on cancer cachexia in patients with cancer of the head, neck, and gastrointestinal track. Head and Neck 2008, 30(1):67-74.
70. McMillan D.C., Wigmore S.J., Fearon K.C., O'Gorman P., Wright C.E., McArdle C.S. Prospective study of megestrol acetate and ibuprofen in gastrointestinal cancer patients with weight loss. British Journal of Cancer 1999, 79(3-4):495-500.
71. Goldberg R.M., Loprinzi C.L., Mailliard J.A., et al. Pentoxifylline for treatment of cancer anorexia and cachexia? A randomized double blind placebo trial. Journal of Clinical Oncology 1995, 13(11):2856-2859.
72. Peuckmann V., Fisch M., Bruera E. Potential novel uses of thalidomide: focus on palliative care. Drugs 2000, 60(2):273-292.
73. Bruera E., Neumann C.M., Pituskin E., Calder K., Ball G., Hanson J. Thalidomide in patients with cachexia due to terminal cancer: preliminary report. Annals of Oncology 1999, 10(7):857-859.
74. Gordon J.N., Trebble T.M., Ellis R.D., Duncan H.D., Johns T., Goggin P.M. Thalidomide in the treatment of cancer cachexia: a randomized placebo controlled trial. Gut 2005, 54(4):540-545.
75. Del Fabbro E., Dev R., Hui D., Palmer L., Bruera E. Effects of melatonin on appetite and other symptoms in patients with advanced cancer and cachexia: a double-blind placebo-controlled trial. Journal of Clinical Oncology 2013 Apr 1, 31(10):1271-1276.
76. Lissoni P. Is there a role for melatonin in supportive care?. Supportive Care in Cancer 2002, 10(2):110-116.
77. Gelato M., McNurlan M., Freedland E. Role of recombinant human growth hormone in HIV-associated wasting and cachexia: pathophysiology and rationale for treatment. Clinical Therapeutics 2007, 29(11):2. 269.
78. Neary N.M., Small C.J., Wren A., et al. Ghrelin increases energy intake in cancer patients with impaired appetite: acute randomized placebo controlled trial. Journal of Clinical Endocrinology and Metabolism 2004, 89(6):2832-2836.
79. García J., Boccia R.V., Graham C., Kumor K., Polvino W. A phase II randomized, placebo-controlled, double-blind study of the efficacy and safety of RC-1291 (RC) for the treatment of cancer cachexia. Journal of Clinical Oncology. ASCO Annual Meeting Proceedings 2007, 25(18S). abstract 9.133.
80. Chlebowski R.T., Bulcavage L., Grosvenor M., et al. Hydrazine sulfate influence on nutritional status and survival in non-small-cell lung cancer. Journal of Clinical Oncology 1990, 8(1):9-15.
81. Kosty M.P., Fleishman S.B., Herndon J.E., et al. Cisplatin, vinblastine, and hydrazine sulfate in advanced, non-small-cell lung cancer: a randomized placebo-controlled, double-blind phase III study of the Cancer and Leukemia Group B. Journal of Clinical Oncology 1994, 12(6):1.113-1.120.
82. Pinto J.A, Folador A., Bonato S.J., et al. Fish oil supplementation in F1 generation associated with naproxen, clenbuterol, and insulin administration reduce tumor growth and cachexia in Walker 256 tumor-bearing rats. Journal of Nutritional Biochemistry 2004, 15(6):358-365.
83. Jatoi A., Alberts S.R., Foster N., et al. Is bortezomib, a proteasome inhibitor, effective in treating cancer-associated weight loss? Preliminary results from the North Central Cancer Treatment Group. Supportive Care in Cancer 2005, 13(6):381-386.
84. Mantovani G., Maccio A., Madeddu C., et al. Randomized phase III clinical trial of five different arms of treatment in 332 patients with cancer cachexia. Oncologist 2010, 15(2):200-211.
85. Mantovani G., Maccio A., Madeddu C., et al. Randomized phase III clinical trial of five different arms of treatment for patients with advanced cancer: interim results. Nutrition 2008, 24(4):305-313.